CCP Fentanyl Sanctions Act
Why China-relevant: Title/Sec.1: 'To authorize sanctions relating to the production and distribution of illicit synthetic narcotics by the People's Republic of China.' Sec.3(a)(1): activities '...in the People's Republic of China, including in Hong Kong and Macau...'; Sec.3(a)(6): 'a covered PRC government entity.'
Path to becoming law
- Introduced
- Passed committee
- Passed House
- Passed Senate
- Sent to President
- Became law
done next step still ahead did not advance
Legislative timeline — dated actions so far
- Filed
Resolved. Model had estimated 4% to become law
- + Bipartisan support (5/8 cosponsors from across the aisle)
- + Broad cosponsorship (8 cosponsors)
- − Sponsor is in the minority party
Legislative likelihood — a tracking indicator, not investment advice.
Signals — secondary, directional
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
Sanctions on PRC fentanyl-precursor producers and chemical/pharma entities pressure China-based chemical/API suppliers.
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |